It has been reported that PD-L1 can deliver PI3K/Akt signals to tumor cells through PD-1 binding and lead to resistance to cancer treatment in multiple myeloma [45], as well as potentially enriching its expression in cancer stem-like cells (CSCs) [46]. The gene discussed is AKT1; the disease is cancer.